Patent ID: 9084815
Filing Date: 2015-07-21
Classification: A61K,A61P

Abstract:
1. A method for treating oral mucositis induced by an anti-tumor agent in a mammalian subject, which comprises administering a pharmaceutically effective amount of (−)-7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-methylpentyl]-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl}heptanoic acid to the subject in need thereof, wherein the subject is receiving the anti-tumor agent that is selected from the group consisting of an alkylating agent, an antimetabolite, an antibiotic, a plant alkaloid, a molecular targeting drug, a hormone, a platinum complex, an antisense, an antibody and RNAi, wherein the molecular targeting drug is selected from the group consisting of imatinib, gefinitib, erlotinib, sorafenib, sunitinib, trastuzumab, rituximab, gemtuzumab-ozogamicin, bevacizumab and cetuximab, the hormone is selected from group consisting of prednisolone, diethylstilbestrol and tamoxifen, the antisense is selected from the group consisting of bcl-2 antisense, hsp27 antisense, XIAP antisense, PKC-alpha antisense and hypoxia-induced factor antisense, the antibody is selected from the group consisting of CD20 antibody, Her2 antibody, VEGF antibody and EGFR antibody, and the RNAi is RNAi targeted Ribonucleotide reductase.